A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

Also called NCT06411275

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 113 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06411275
Other papers using this trial's data
  • Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial JAMA network open, 2025-03-03 DOI, PubMed 40029660, PMC11877176 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06411275. Randomized; double masking; primary purpose treatment. Start 2022-03-31 (actual); primary completion 2023-01-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
HTD1801
Intervention (Drug)
Placebo
Intervention (Drug)
HTD1801
Lead sponsor
Shenzhen HighTide Biopharmaceutical Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06411275
Content hash
fbc720e3c7b4f03d45de5cc6d7dd732110d868d442d00659db1c8fe25419abf7